Cassava Sciences, Inc.

NasdaqCM SAVA

Cassava Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -78.07 M

Cassava Sciences, Inc. Free Cash Flow is USD -78.07 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 3.70% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Cassava Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -81.07 M, a -20.41% change year over year.
Cassava Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -67.33 M, a -46.86% change year over year.
Cassava Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -45.84 M, a -855.88% change year over year.
Cassava Sciences, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -4.80 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: SAVA

Cassava Sciences, Inc.

CEO	Mr. Richard Jon Barry
IPO Date	July 14, 2000
Location	United States
Headquarters	7801 North Capital of Texas Highway
Employees	29
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key trends

Past 5 years